Clinical Trials
18 trialsNCT07085728 2026-05-15
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05020236 2026-05-05
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06574568 2026-02-05
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Excyte Biopharma Ltd
Phase 1 Recruiting
NCT06049290 2025-12-04
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT07247097 2025-11-25
ELDORADO
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT03602235 2025-10-21
High Dose Ascorbic Acid for Plasma Cell Disorders
University of Iowa
Phase 1 Completed
NCT01125449 2025-05-18
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
Phase 2 Withdrawn
NCT06425276 2024-05-23
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
CASI Pharmaceuticals (China) Co., Ltd.
Phase 4 Completed
NCT06082596 2023-10-13
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
BeBetter Med Inc
Phase 1 Completed
NCT05438394 2023-04-14
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Peking University People's Hospital
Phase 1 Unknown
NCT05052970 2022-02-01
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1 Unknown
NCT04288765 2021-07-09
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Grupo Cooperativo de HemopatÃas Malignas
Phase 3 Withdrawn
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01660633 2020-04-21
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00925782 2019-12-17
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT02669615 2018-10-10
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT01148108 2013-03-15
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
Telik
Phase 2 Completed